PHK
KALV

Point72 Hong Kong’s KalVista Pharmaceuticals KALV Stock Holding History

Point72 Hong Kong’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,646
Closed -$26K – 2170
2022
Q2 		$26K Buy
+2,646
New +$29.2K ﹤0.01% 1504
2022
Q1 		– Sell
-1,005
Closed -$13K – 2094
2021
Q4 		$13K Buy
+1,005
New +$16K ﹤0.01% 1608
2019
Q4 		– Sell
-142
Closed -$2K – 1304
2019
Q3 		$2K Buy
+142
New +$2.29K ﹤0.01% 870

Other funds holding KALV

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Hong Kong's KALV Position: Q3 2022 in Review

Point72 Hong Kong sold out of KalVista Pharmaceuticals (KALV) in Q3 2022, closing a stake of 2,646 shares — an estimated $26K sold.

Point72 Hong Kong first reported a position in KALV in Q3 2019 and held it in 3 quarters. The position peaked at $26K in Q2 2022. 94 funds tracked by Wall St. Rank hold KALV as of Q3 2022.

  • Point72 Hong Kong reported no remaining KalVista Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 2,646 KalVista Pharmaceuticals shares in Q3 2022, an estimated $26K.
  • Point72 Hong Kong first reported a position in KalVista Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Point72 Hong Kong's KalVista Pharmaceuticals position peaked at $26K in Q2 2022.
  • 94 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.